Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU

Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that inhibit the progression of tissue fibrosis, is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In clinical trials in patients with mild to moderate IPF, oral pirfenidone generally provided a reduced rate of decline in forced vital capacity, while prolonging progression-free survival and reducing the risk of IPF-related and all-cause mortality. Pirfenidone has a manageable tolerability profile; however, gastrointestinal and skin-related events are common. Data from longer-term and real-world studies of pirfenidone use in patients with IPF are consistent with those in clinical trials. © 2016, Springer International Publishing Switzerland.